EC
OLMA icon

EcoR1 Capital’s Olema Pharmaceuticals OLMA Stock Holding History

EcoR1 Capital’s Portfolio OLMA Stock Details OLMA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q3 		– Sell
-353,701
Closed -$1.44M – 84
2022
Q2 		$1.44M Buy
+353,701
New +$1.12M 0.05% 65

Other funds holding OLMA

BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
LGM
Logos Global Management San Francisco, California $2B AUM 444.09% 1-Year Est. Return
CAM
Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
KCM
Kynam Capital Management Princeton, New Jersey $1.62B AUM 138.67% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
FFM
Fairmount Funds Management West Conshohocken, Pennsylvania $1.38B AUM 407.79% 1-Year Est. Return

EcoR1 Capital's OLMA Position: Q3 2022 in Review

EcoR1 Capital sold out of Olema Pharmaceuticals (OLMA) in Q3 2022, closing a stake of 353,701 shares — an estimated $1.44M sold.

EcoR1 Capital first reported a position in OLMA in Q2 2022 and held it in 1 quarter. The position peaked at $1.44M in Q2 2022. 73 funds tracked by Wall St. Rank hold OLMA as of Q3 2022.

  • EcoR1 Capital reported no remaining Olema Pharmaceuticals position as of Q3 2022 after selling out during the quarter.
  • EcoR1 Capital sold 353,701 Olema Pharmaceuticals shares in Q3 2022, an estimated $1.44M.
  • EcoR1 Capital first reported a position in Olema Pharmaceuticals in Q2 2022 and held it in 1 quarter.
  • EcoR1 Capital's Olema Pharmaceuticals position peaked at $1.44M in Q2 2022.
  • 73 funds tracked by Wall St. Rank held Olema Pharmaceuticals as of Q3 2022.

Based on EcoR1 Capital's 13F filing for Q3 2022, filed 14 Nov 2022.